AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19139440
Drug: IFN‐alpha‐2b 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks followed by IFN‐alpha‐2b 10 x 10(6) U administered subcutaneously three times a week for 48 weeks (arm B)
Trial: 9781830
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (50 mg)
Trial: 9781830
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release dipyridamole (400 mg/day)
Trial: 7830201
Drug: Stabilization splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilization splint treatment (experimental group)
Trial: 9090684
Drug: Oral dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dihydroergotamine (DHE)
Trial: 27440869
Drug: Golimumab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (any dose)
Trial: 19171629
Drug: Psychostimulant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychostimulant medications for ADHD
Trial: 22854901
Drug: Carbamazepine up
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine up to 600 mg/day
Trial: 12617742
Drug: 80 ml
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 ml contrast material injected before CT scan (group 1; n=7)
Trial: 12617742
Drug: 80 ml
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 ml contrast material injected before CT scan (group 2; n=7)
Trial: 2108884
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day leuprorelin given subcutaneously plus 250 mg flutamide three times a day
Trial: 2108884
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day leuprorelin given subcutaneously
Trial: 2108884
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of leuprorelin and flutamide
Trial: 6446008
Drug: Terbutaline 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.50 mg by aerosol inhalation
Trial: 6446008
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 0.04 mg by aerosol inhalation
Trial: 31179798
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical treatment and physical therapy program)
Trial: 31847717
Drug: 1-month treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month treatment with inhaled budesonide (200 μg, twice daily)
Trial: 31847717
Drug: 2-month treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-month treatment with inhaled budesonide (200 μg, twice daily)
Trial: 31847717
Drug: 4-month treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month treatment with inhaled budesonide (200 μg, twice daily)
Trial: 25012275
Drug: Yoga practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga practice (1 hour daily for 3 months)
Trial: 20483664
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH (150 IU daily for 7 days)
Trial: 16271907
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone 2.5 mg/day
Trial: 10451805
Drug: Metoclopramide (MCP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP), 5 mg every 8 hours for 2 months
Trial: 10451805
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered every 8 hours for 2 months
Trial: 7598054
Drug: High-resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-resistant starch diet (39.0 +/- 3.0 g/d)
Trial: 7598054
Drug: Low-resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-resistant starch diet (5.0 +/- 0.4 g/d)
Trial: 115562
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (50 ml/kg of amino acid solution with 10 or 25 g/dl glucose plus 500 ml of soybean emulsion for 24 hours before and 5 days after operation)
Trial: 31353177
Drug: Spinal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal morphine 0.1 mg (group M+)
Trial: 31353177
Drug: Posterior quadratus
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior quadratus lumborum block using 0.3% ropivacaine (0.45 mL/kg each side, maximum 150 mg) (group pQ+)
Trial: 26323451
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and Root Planing (SRP) with adjunctive Tetracycline Fibers
Trial: 26323451
Drug: Both SRP
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SRP and SRP with adjunctive Tetracycline Fibers
Trial: 22091563
Drug: Once‐yearly intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐yearly intravenous (IV) ZOL 5 mg
Trial: 19331488
Drug: 0.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 g/kg alcohol (placebo)
Trial: 12950437
Drug: Reversible inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversible inhibitors of monoamine oxidase type A (RIMAs)
Trial: 12950437
Drug: SSRIs (fluvoxamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (fluvoxamine, paroxetine, sertraline)
Trial: 12950437
Drug: Gabergic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabergic drugs (clonazepam, gabapentin, pregabalin)
Trial: 12950437
Drug: Buspirone, tricyclics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone, tricyclics, beta-blockers
Trial: 12950437
Drug: Paroxetine, clonazepam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine, clonazepam, sertraline, brofaromine
Trial: 9132323
Drug: Aceclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac (100 mg bid)
Trial: 1862787
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam 0.12 mg/kg
Trial: 1862787
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam 0.20 mg/kg
Trial: 30869183
Drug: Insulin degludec/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/insulin aspart (IDegAsp) twice daily
Trial: 30869183
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (BIAsp 30) twice daily
Trial: 15285979
Drug: Low-dose cortisol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cortisol (10 mg/day) for 1 month
Trial: 9502664
Drug: Misoprostol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (50 mcg every 4 hours until delivery)
Trial: 9502664
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (0.5 mg) followed by intravenous oxytocin infusion (Control)
Trial: 2898457
Drug: BRL 26830A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 26830A 50 mg qid
Trial: 11595776
Drug: Orlistat therapy
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat therapy
Trial: 29659879
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (off orlistat)
Trial: 26571891
Drug: Plum blossom
RxNorm normalized name: OCTISALATE 4.7 g in 100 g / ZINC OXIDE 15 g in 100 g TOPICAL LIPSTICK [TATCHA THE KISSU LIP TINT SPF 25 PLUM BLOSSOM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plum blossom needle tapping therapy at key points combined with Bobath therapy
Trial: 26571891
Drug: Bobath manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bobath manipulation therapy
Trial: 24260334
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions, 5 days/week, 60 minutes each, 100% oxygen at 1.5 ATA
Trial: 21148720
Drug: rSP-C surfactant
RxNorm normalized name: surfactant protein-D homotrimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rSP-C surfactant (up to eight doses administered over 96 hours)
Trial: 9951781
Drug: Clodronate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 100 mg i.m. every week
Trial: 9951781
Drug: Clodronate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 100 mg i.m. every two weeks
Trial: 8537627
Drug: Silver-impregnated cuff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver-impregnated cuff (Ag-CC)
Trial: 1968858
Drug: Scoring system
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scoring system for calculating the dose of vaginal prostaglandin E2 tablets
Trial: 1968858
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 3 mg vaginal prostaglandin E2 tablets
Trial: 29947083
Drug: Burosumab 1
RxNorm normalized name: Burosumab 10 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burosumab 1 mg/kg subcutaneously every 4 weeks (n = 68)
Trial: 27357971
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celecoxib (loading dose the night before surgery then twice daily for 10 days)
Trial: 20814217
Drug: Platelet gel
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet gel (PG) applied locally
Trial: 17413292
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone infusion (2.3 microg/kg/h)
Trial: 12151889
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Hohmann operation)
Trial: 2107518
Drug: Haemophilus b
RxNorm normalized name: HAEMOPHILUS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus b conjugate vaccine (meningococcal protein conjugate), PedvaxHIB (PRP‐OMPC)
Trial: 373391
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dosage of clomipramine (150 mg at night for 10 days)
Trial: 373391
Drug: Divided daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided daily dosage of clomipramine (150 mg three times daily for 10 days)
Trial: 373391
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dosage of clomipramine
Trial: 373391
Drug: Divided daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided daily dosage of clomipramine
Trial: 30832230
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of Glutamine (Gln) for 14 days
Trial: 30899946
Drug: SRP followed
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP followed by topical use of rhubarb extract
Trial: 16275936
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) with autologous stem-cell transplantation (melphalan 200 mg/m2 IV or melphalan 140 mg/m2 IV plus busulfan 16 mg/kg orally)
Trial: 16275936
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (CCT; monthly courses of vincristine, melphalan, cyclophosphamide, and prednisone)
Trial: 12561063
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of Tc‐99m tin colloid (0.4‐5 microm)
Trial: 12561063
Drug: Subdermal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal injection of radiocolloids
Trial: 2268864
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 to 40 mg daily for six months)
Trial: 6104614
Drug: Nadolol (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (once daily for 12 weeks)
Trial: 31734589
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative body radiotherapy (SABR) at a dose of 20Gy in 1 fraction to each metastasis
Trial: 30192018
Drug: Ecopipam (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam (50 mg/day for weight <34 kg, 100 mg/day for weight >34 kg)
Trial: 27434094
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone alone (90 mg once daily)
Trial: 27434094
Drug: Estradiol addition
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol addition (2 mg twice daily)
Trial: 25112096
Drug: Electric-thermal Bian-stone
RxNorm normalized name: ditch stonecroft extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electric-thermal Bian-stone therapy (group A)
Trial: 25112096
Drug: Moxibustion box
RxNorm normalized name: ALLERGENIC EXTRACT, BOX ELDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion box therapy (group B)
Trial: 22804796
Drug: 12-week exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week exercise programme including pelvic floor muscle training (PFMT), conducted between 20 and 36 weeks of gestation, with one weekly group session led by physiotherapists and home exercises encouraged at least twice a week.
Trial: 19464164
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) in triple-negative tumours
Trial: 19464164
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) in HER2-positive tumours
Trial: 17594986
Drug: I'm-Yunity (Coriolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I'm-Yunity (Coriolus versicolor) 1200 mg, three times daily for 14 days
Trial: 15446758
Drug: NK-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK-1 receptor antagonists (specific drug not mentioned), administered before chemotherapy and continued twice daily for five days.
Trial: 15446758
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with granisetron and dexamethasone.
Trial: 15446758
Drug: NK-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK-1 receptor antagonists (specific drug not mentioned), cost of Can$6.60 per dose.
Trial: 15446758
Drug: NK-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK-1 receptor antagonists (specific drug not mentioned), total cost for five days of therapy.
Trial: 29273485
Drug: Omnitrope (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnitrope (0.08 or 0.16mg GH/kg/wk divided into 7 equal daily doses)
Trial: 18827177
Drug: 10 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg/kg bevacizumab (Avastin) administered every 2 weeks
Trial: 15940776
Drug: ATP 90
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP 90 mg once daily
Trial: 8317411
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg (three premeal doses)
Trial: 8317411
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (single morning dose)
Trial: 28806907
Drug: Estazolam (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam (1-2 mg/day taken 30 minutes before sleep for 4 weeks)
Trial: 21672316
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml 6% hydroxyethyl starch 130/0.4 (HES)
Trial: 21672316
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml 4% succinylated gelatine (GEL)
Trial: 16513858
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (40 mg)
Trial: 16513858
Drug: Osmotic-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic-release methylphenidate (90 mg)
Trial: 12753943
Drug: CEE+MPA (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+MPA (0.625 mg conjugated equine estrogens combined with 2.5 mg medroxyprogesterone acetate)
Trial: 6963097
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administration during maintenance therapy with digoxin
Trial: 6963097
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administration during maintenance therapy with digitoxin
Trial: 6963097
Drug: Fibre administration
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre administration
Trial: 26474237
Drug: Low-dose rifaximin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rifaximin (400mg every 12 hours for 2 weeks)
Trial: 26474237
Drug: High-dose rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose rifaximin (600mg every 12 hours for 2 weeks)
Trial: 26474237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rifaximin treatment)
Trial: 9218083
Drug: Zamifenacin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zamifenacin 40 mg
Trial: 9218083
Drug: Zamifenacin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zamifenacin 10 mg
Trial: 7752825
Drug: 500 mcg
RxNorm normalized name: Nplate 500 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mcg of selenium (as sodium selenite) followed by 100 mg coenzyme Q10 (Bio‐Quinone) and 100 mcg selenium (Bio‐Selenium in the form of 1‐seleno‐methionine) for one year
Trial: 7752825
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo preparations
Trial: 3054778
Drug: Ceftriaxone, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 80 to 100 mg/kg/day for 4 days
Trial: 31473324
Drug: Normothermia and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermia and early treatment of fever (≥37.8°C)
Trial: 28343218
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (50 mg/kg)
Trial: 26604728
Drug: Mud Bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud Bath Therapy (MBT), n=22
Trial: 18788410
Drug: Erythropoietin stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin stimulating agents (ESAs) treatment targeting higher hemoglobin levels (near normal level)
Trial: 18788410
Drug: Erythropoietin stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin stimulating agents (ESAs) treatment targeting lower hemoglobin levels (sub-normal level)
Trial: 9186459
Drug: Octreotide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (200 micrograms intravenous)
Trial: 1586104
Drug: Zidovudine, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 1200 mg/d
Trial: 9229416
Drug: Multimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality therapy
Trial: 29738282
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg/kg BM
Trial: 22293631
Drug: Genistein 300
RxNorm normalized name: calcium carb,citrate/vitamin D3/mineral comb no.34/genistein 300 mg-200 unit-13.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein 300 mg/d
Trial: 22293631
Drug: Genistein 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein 600 mg/d
Trial: 17235043
Drug: Pertuzumab 420
RxNorm normalized name: pertuzumab 420 MG in 14 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab 420 mg (loading dose of 840 mg)
Trial: 17235043
Drug: Pertuzumab 1,050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab 1,050 mg
Trial: 401699
Drug: Fenoprofen (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoprofen (2,400 mg/day)
Trial: 401699
Drug: Aspirin (3,900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3,900 mg/day)